Iterum Therapeutics plc (ITRMF) Stock Overview
Explore Iterum Therapeutics plc’s financial performance, market position, analyst ratings, and future outlook.
Iterum Therapeutics plc (ITRMF)
Key Financials
Key Financials
Market Cap
2.7M
P/E Ratio
-0.10
EPS (TTM)
$-0.70
ROE
4.42%
ITRMF Stock Analysis & Investment Overview (PNK)
Our AI-powered analysis of Iterum Therapeutics plc (PNK: ITRMF) gives investors deep insight into how the stock performs on the PNK exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Iterum Therapeutics plc's PNK-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of ITRMF on the PNK shows an RSI of 37.99, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $0.00 for the PNK listing.
Key metrics behind Iterum Therapeutics plc's PNK-traded stock include a P/E ratio of -0.10 and a market capitalization of 2.7M. Combined with our AI analysis, these give both institutional and retail investors a clear view of ITRMF on the PNK.